source
- Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drugWerewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed to merge with Werewolf in an all-stock deal and raised $150 million, positioning the biotech to take…Fierce Biotech · 9h ago↗ source
- Moderna's cancer vaccine boost lifts stock, sparks talk of Keytruda-like reachModerna’s shares surged 177% after a phase 3 topline win for its Merck‑partnered cancer vaccine, intismeran autogene, was disclosed. The data, released on Wednesday, added roughly $45 billion to Mo…